文献速递膀胱癌与上尿路尿路上皮癌

晚期尿路上皮癌一线免疫检查点抑制剂治疗的新预后模型

A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
PubMed 文献 · Eur Urol Oncol · 2021-01-07

本研究基于24家机构、5个国家的984例晚期尿路上皮癌患者,最终纳入357例接受一线免疫检查点抑制剂治疗的患者,开发了一个新的总生存预后风险评分。多因素分析显示ECOG评分≥2、白蛋白<3.5 g/dl、中性粒细胞与淋巴细胞比值>5和肝转移是显著预后因素,风险评分的C指数为0.68(95%CI 0.65-0.71)。

要点

  • ECOG≥2、白蛋白<3.5 g/dl、NLR>5和肝转移各计1分,评分越高总生存越差。
  • 新风险评分C指数为0.68(95%CI 0.65-0.71)。
  • 该评分有助于治疗讨论和临床试验设计,尚需外部验证。

核心结论

  • 开发了一个基于美国与欧洲临床试验外晚期尿路上皮癌患者的一线免疫检查点抑制剂总生存风险评分。
  • 评分组成因素均为易获取的肿瘤生物学与治疗反应相关指标,外部验证正在进行中。

研究设计与样本

  • 多中心回顾性队列研究,纳入24家机构、5个国家(美国和欧洲)临床试验外接受一线免疫检查点抑制剂治疗的晚期尿路上皮癌患者。
  • 共984例患者,最终357例纳入分析,平均年龄71岁,27%为女性,68%为纯尿路上皮癌,13%为上尿路尿路上皮癌。

主要发现

  • 多因素分析中,ECOG评分≥2、白蛋白<3.5 g/dl、中性粒细胞与淋巴细胞比值>5和肝转移为显著预后因素并纳入风险评分。
  • 新一线风险评分的C指数为0.68(95%CI 0.65-0.71)。

关键数值与推荐

  • 基于18个假设与总生存相关的协变量进行单变量Cox回归,p<0.2者进入多变量分析,p<0.05者纳入最终模型。
  • 根据beta系数为保留的协变量赋值构建风险评分,并计算分层中位总生存和C统计量。

临床怎么用

  • 该风险评分可能有助于接受一线免疫检查点抑制剂治疗的晚期尿路上皮癌患者的治疗讨论和结局估计。
  • 评分也可能影响临床试验设计和终点选择。

局限性

  • 研究为回顾性性质。
  • 缺乏外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers (except for PD-L1). OBJECTIVE: We aimed to develop a prognostic model for overall survival (OS) in patients receiving 1L ICIs for advanced urothelial cancer (aUC) in a multicenter cohort study. DESIGN, SETTING, AND PARTICIPANTS: Patients treated with 1L ICIs for aUC across 24 institutions and five countries (in the USA and Europe) outside clinical trials were included in this study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used a stepwise, hypothesis-driven approach using clinician-selected covariates to develop a new risk score for patients receiving ICIs in the 1L setting. Demographics, clinicopathologic data, treatment patterns, and OS were collected uniformly. Univariate Cox regression was performed on 18 covariates hypothesized to be associated with OS based on published data. Variables were retained for multivariate analysis (MVA) if they correlated with OS (p < 0.2) and were included in the final model if p < 0.05 on MVA. Retained covariates were assigned points based on the beta coefficient to create a risk score. Stratified median OS and C-statistic were calculated. RESULTS AND LIMITATIONS: Among 984 patients, 357 with a mean age of 71 yr were included in the analysis, 27% were female, 68% had pure UC, and 13% had upper tract UC. Eastern Cooperative Oncology Group performance status ≥2, albumin <3.5 g/dl, neutrophil:lymphocyte ratio >5, and liver metastases were significant prognostic factors on MVA and were included in the risk score. C index for new 1L risk score was 0.68 (95% confidence interval 0.65-0.71). Limitations include retrospective nature and lack of external validation. CONCLUSIONS: We developed a new 1L ICI risk score for OS based on data from patients with aUC treated with ICIs in the USA and Europe outside of clinical trials. The score components highlight readily available factors related to tumor biology and treatment response. External validation is being pursued. PATIENT SUMMARY: With multiple new treatments under development and approved for advanced urothelial carcinoma, it can be difficult to identify the best treatment sequence for each patient. The risk score may help inform treatment discussions and estimate outcomes in patients treated with first-line immune checkpoint inhibitors, while it can also impact clinical trial design and endpoints. TAKE HOME MESSAGE: A new risk score was developed for advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors. The score assigned Eastern Cooperative Oncology Group performance status ≥2, albumin <3.5 g/dl, neutrophil:lymphocyte ratio >5, and liver metastases each one point, with a higher score being associated with worse overall survival.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Khaki AR, Li A, Diamantopoulos LN, et al. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021. PMID: 33423945. doi:10.1016/j.euo.2020.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。